^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

SRC-family kinase (SFK) inhibitor

9d
The regulation of organic anion transporting polypeptide 1B1 by nonreceptor tyrosine kinase YES1. (PubMed, Drug Metab Dispos)
In this study, OATP1B1 uptake function was found to be significantly suppressed by SRC proto-oncogene, non-receptor tyrosine kinase family kinase inhibitors, with SU6656 demonstrating the most potent inhibitory effect...Abrogation of Caveolin-1 exhibited no effect on the interaction between YES-1 and OATP1B1 but reduced the phosphorylation level of the transporter. Taken together, inhibitors of YES-1 may alter the uptake function of OATP1B1, potentially leading to drug-drug interactions related to post-translational modification.
Journal
|
CAV1 (Caveolin 1) • SRC (SRC Proto-Oncogene)
|
SU6656
4ms
CCT196969 inhibits TNBC by targeting the HDAC5/RXRA/ASNS axis to down-regulate asparagine synthesis. (PubMed, J Exp Clin Cancer Res)
This study reveals a previously unrecognized anti-TNBC mechanism of CCT196969 through the HDAC5/RXRA/ASNS axis. This provides potential candidate targets for the treatment of TNBC and a theoretical basis for the clinical treatment of TNBC patients with CCT196969.
Journal
|
ASNS (Asparagine synthetase) • HDAC5 (Histone Deacetylase 5) • RXRA (Retinoid X Receptor Alpha)
|
CCT196969 • MG132
9ms
FGR Src family kinase causes signaling and phenotypic shift mimicking retinoic acid-induced differentiation of leukemic cells. (PubMed, Oncotarget)
Thus, FGR triggers signaling events and phenotypic shifts characteristic of RA. This finding represents a paradigm shift, given FGR's historical role as a pro-proliferation oncogene.
Journal • IO biomarker
|
CD38 (CD38 Molecule) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • ITGAM (Integrin, alpha M) • LCP2 (Lymphocyte cytosolic protein 2)
10ms
Mindin regulates fibroblast subpopulations through distinct Src family kinases during fibrogenesis. (PubMed, JCI Insight)
Moreover, in the context of the fibrotic microenvironment of the tumor stroma, we found that differential responses of resident fibroblast subpopulations to Mindin extend to the generation of functionally heterogeneous cancer-associated fibroblasts. This study identifies Mindin as a key orchestrator of dermal fibroblast heterogeneity, reshaping cellular dynamics and signaling diversity in the complex landscapes of skin fibrosis and cancer.
Journal
|
DPP4 (Dipeptidyl Peptidase 4)
11ms
Mindin/spondin-2 regulates fibroblast subpopulations through distinct Src family kinases during fibrogenesis. (PubMed, JCI Insight)
Moreover, in the context of the fibrotic microenvironment of the tumour stroma, we found that differential responses of resident fibroblasts subpopulations to Mindin extend to the generation of functionally heterogeneous cancer-associated fibroblasts (CAFs). This study unveils Mindin as a key orchestrator of dermal fibroblast heterogeneity, reshaping cellular dynamics and signalling diversity in the complex landscapes of skin fibrosis and cancer.
Journal
|
DPP4 (Dipeptidyl Peptidase 4)
12ms
An SH3-binding allosteric modulator stabilizes the global conformation of the AML-associated Src-family kinase, Hck. (PubMed, J Biol Chem)
Cellular thermal shift assays confirmed SH3 domain-dependent interaction of PDA1 with wild-type Hck in myeloid leukemia cells and with a kinase domain gatekeeper mutant (T338M). These results identify PDA1 as a starting point for Src-family kinase allosteric inhibitor development that may work in concert with ATP-site inhibitors to suppress the evolution of resistance.
Journal
|
HCK (HCK Proto-Oncogene)
1year
Cocrystallization of the Src-Family Kinase Hck with the ATP-Site Inhibitor A-419259 Stabilizes an Extended Activation Loop Conformation. (PubMed, Biochemistry)
In cancer cells where Hck is constitutively active, the extended autophosphorylation loop may render Hck more sensitive to inhibitors like A-419259 which prefer this kinase conformation. More generally, these results provide additional insight into targeted kinase inhibitor design and how conformational preferences of inhibitors may impact selectivity and potency.
Journal
|
HCK (HCK Proto-Oncogene)
over1year
STOP-IPF: Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov)
P1/2, N=49, Active, not recruiting, National Jewish Health | Recruiting --> Active, not recruiting
Enrollment closed
|
saracatinib (AZD0530)
over1year
STOP-IPF: Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov)
P1/2, N=49, Recruiting, National Jewish Health | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Sep 2024
Trial completion date • Trial primary completion date
|
saracatinib (AZD0530)
2years
Integrated signaling and transcriptome analysis reveals Src family kinase individualities and novel pathways controlled by their constitutive activity. (PubMed, Front Immunol)
Furthermore, we show that Lck- and Lyn-generated signals suffice to induce transcriptome alterations, reminiscent of B-cell activation, in the absence of receptor/co-receptor engagement. Finally, our analyses revealed a yet unrecognized role of SFKs in tipping the balance of cellular stress responses, by promoting the onset of ER-phagy, an as yet completely uncharacterized process in B lymphocytes.
Journal
|
LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase)
over2years
Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma. (PubMed, Clin Cancer Res)
The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every two weeks was safe and tolerable. This combination had a disease control rate of 22% at five months.
P1 data • Journal
|
dasatinib • ganitumab (AMG 479)
over2years
Src family kinases engage differential pathways for encapsulation into extracellular vesicles. (PubMed, J Extracell Biol)
Collectively, the data suggest that different EVs biogenesis pathways exist and can regulate the encapsulation of specific proteins into EVs. This study provides an understanding of the EVs heterogeneity created by different EVs biogenesis pathways.
Journal
|
TSG101 (Tumor Susceptibility 101)